About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2010 (2010), Article ID 271504, 13 pages
http://dx.doi.org/10.1155/2010/271504
Review Article

Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems

11st Division of Infectious Diseases, “Luigi Sacco” Hospital, Via GB Grassi, 74, 20157 Milan, Italy
2Clinical Pharmacology Unit, “Luigi Sacco” Hospital, 20157 Milan, Italy

Received 28 April 2010; Revised 15 August 2010; Accepted 7 September 2010

Academic Editor: Gloria L. Vega

Copyright © 2010 Sara Melzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Danesh, R. Collins, and R. Peto, “Chronic infections and coronary heart disease: is there a link?” The Lancet, vol. 350, no. 9075, pp. 430–436, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. K. J. Mattila, V. V. Valtonen, M. S. Nieminen, and S. Asikainen, “Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke,” Clinical Infectious Diseases, vol. 26, no. 3, pp. 719–734, 1998. View at Google Scholar · View at Scopus
  3. S. E. Epstein, Y. F. Zhou, and J. Zhu, “Infection and atherosclerosis: emerging mechanistic paradigms,” Circulation, vol. 100, no. 4, pp. e20–e28, 1999. View at Google Scholar · View at Scopus
  4. C. R. Meier, S. S. Jick, L. E. Derby, C. Vasilakis, and H. Jick, “Acute respiratory-tract infections and risk of first-time acute myocardial infarction,” The Lancet, vol. 351, no. 9114, pp. 1467–1471, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Grunfeld and K. R. Feingold, “Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense,” Proceedings of the Society for Experimental Biology and Medicine, vol. 200, no. 2, pp. 224–227, 1992. View at Google Scholar · View at Scopus
  6. M. Leinonen and P. Saikku, “Evidence for infectious agents in cardiovascular disease and atherosclerosis,” Lancet Infectious Diseases, vol. 2, no. 1, pp. 11–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Zhu, A. A. Quyyumi, J. E. Norman et al., “Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels,” American Journal of Cardiology, vol. 85, no. 2, pp. 140–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Roivainen, G. Alfthan, P. Jousilahti, M. Kimpimäki, T. Hovi, and J. Tuomilehto, “Enterovirus infections as a possible risk factor for myocardial infarction,” Circulation, vol. 98, no. 23, pp. 2534–2537, 1998. View at Google Scholar · View at Scopus
  9. L. Broxmeyer, “Heart disease: the greatest 'risk' factor of them all,” Medical Hypotheses, vol. 62, no. 5, pp. 773–779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Rasheed, J. S. Yan, A. Lau, and A. S. Chan, “HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study,” PLoS ONE, vol. 3, no. 8, Article ID e3003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. K. Hellerstein, C. Grunfeld, K. Wu et al., “Increased de novo hepatic lipogenesis in human immunodeficiency virus infection,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 3, pp. 559–565, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Riddler, E. Smit, S. R. Cole et al., “Impact of HIV infection and HAART on serum lipids in men,” Journal of the American Medical Association, vol. 289, no. 22, pp. 2978–2982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Anderson, “Infection, antibiotics, and atherothrombosis—end of the road or new beginnings?” The New England Journal of Medicine, vol. 352, no. 16, pp. 1706–1709, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Cicognani, M. Malavolti, A. M. Morselli-Labate, L. Zamboni, C. Sama, and L. Barbara, “Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis,” Archives of Internal Medicine, vol. 157, no. 7, pp. 792–796, 1997. View at Google Scholar · View at Scopus
  15. J. S. Currier, J. D. Lundgren, A. Carr et al., “Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy,” Circulation, vol. 118, no. 2, pp. e29–e35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Lai, E. K. Fishman, H. Lai et al., “Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms,” Clinical Infectious Diseases, vol. 46, no. 4, pp. 600–610, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Martínez, A. Milinkovic, E. Buira et al., “Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area,” HIV Medicine, vol. 8, no. 4, pp. 251–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. E. A. Eugenin, S. Morgello, M. E. Klotman et al., “Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease,” American Journal of Pathology, vol. 172, no. 4, pp. 1100–1111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. F. J. Torriani, L. Komarow, R. A. Parker et al., “Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. The ACTG (AIDS Clinical Trials Group) study 5152s,” Journal of the American College of Cardiology, vol. 52, no. 7, pp. 569–576, 2008. View at Publisher · View at Google Scholar
  20. D. Francisci, S. Giannini, F. Baldelli et al., “HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction,” AIDS, vol. 23, no. 5, pp. 589–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. SMART Study Group, “CD4+-guided interruption of antiretroviral treatment,” The New England Journal of Medicine, vol. 355, pp. 2283–2296, 2006. View at Google Scholar
  22. P. Tebas, W. K. Henry, R. Matining et al., “Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk,” PLoS ONE, vol. 3, no. 4, Article ID e2021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Friis-Møller, P. Reiss, C. A. Sabin et al., “Class of antiretroviral drugs and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 356, no. 17, pp. 1723–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. W. Worm, C. Sabin, R. Weber et al., “Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study,” Journal of Infectious Diseases, vol. 201, no. 3, pp. 318–330, 2010. View at Publisher · View at Google Scholar
  25. D. Cooper, M. Bloch, A. Humphries, et al., “Simplification with fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in adults with suppressed HIV replication: the STEAL study, a randomized, open-label, 96-week, non-inferiority trial,” in Proceedings of the 16th Conference on Retroviruses and. Opportunistic Infections (CROI '10), Montréal, Canada, February 2009, abstract no. 576.
  26. E. Martínez, J. A. Arranz, D. Podzamczer et al., “A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 3, pp. 290–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. E. Sax, C. Tierney, A. C. Collier et al., “Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy,” The New England Journal of Medicine, vol. 361, no. 23, pp. 2230–2240, 2009. View at Publisher · View at Google Scholar
  28. S. Walmsley, A. Avihingsanon, J. Slim et al., “Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-I therapy in adults,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 4, pp. 367–374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Eron Jr., P. Yeni, J. Gathe Jr. et al., “The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial,” The Lancet, vol. 368, no. 9534, pp. 476–482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-M. Molina, J. Andrade-Villanueva, J. Echevarria et al., “Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study,” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 3, pp. 323–332, 2010. View at Publisher · View at Google Scholar
  31. A. M. Mills, M. Nelson, D. Jayaweera et al., “Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis,” AIDS, vol. 23, no. 13, pp. 1679–1688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. P. Dubé, J. H. Stein, J. A. Aberg et al., “Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group,” Clinical Infectious Diseases, vol. 37, no. 5, pp. 613–627, 2003. View at Publisher · View at Google Scholar
  33. http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf.
  34. A. Milinkovic, E. Martinez, S. López et al., “The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients,” Antiviral Therapy, vol. 12, no. 3, pp. 407–415, 2007. View at Google Scholar · View at Scopus
  35. J. M. Llibre, P. Domingo, R. Palacios et al., “Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir,” AIDS, vol. 20, no. 10, pp. 1407–1414, 2006. View at Publisher · View at Google Scholar
  36. A. Viganò, G. M. Aldrovandi, V. Giacomet et al., “Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children,” Antiviral Therapy, vol. 10, no. 8, pp. 917–924, 2005. View at Google Scholar · View at Scopus
  37. D. Salmon-Ceron, A. Lazzarin, E. Van Wijngaerden et al., “Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results,” Clinical Infectious Diseases, vol. 44, no. 11, pp. 1484–1492, 2007. View at Publisher · View at Google Scholar
  38. G. J. Class, B. Jülg, J. Röling, F. D. Goebel, and J. R. Bogner, “Metabolic and anthropometric changes one year after switching from Didanosine/Stavudine to Tenofovir in HIV-infected patients,” European Journal of Medical Research, vol. 12, no. 2, pp. 54–60, 2007. View at Google Scholar · View at Scopus
  39. M. A. Valantin, R. Bittar, P. de Truchis et al., “Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 3, pp. 556–561, 2010. View at Publisher · View at Google Scholar
  40. J.-J. Parienti, V. Massari, D. Rey, P. Poubeau, and R. Verdon, “Efavirenz to nevirapine switch in HIV-1—infected patients with dyslipidemia: a randomized, controlled study,” Clinical Infectious Diseases, vol. 45, no. 2, pp. 263–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Eron, B. Young, D. A. Cooper et al., “Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials,” The Lancet, vol. 375, no. 9712, pp. 396–407, 2010. View at Publisher · View at Google Scholar
  42. P. Tebas, J. Zhang, K. Yarasheski et al., “Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s),” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 2, pp. 193–200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. A. J. Busti, R. Bedimo, D. M. Margolis, and D. S. Hardin, “Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir,” Journal of Investigative Medicine, vol. 56, no. 2, pp. 539–544, 2008. View at Google Scholar · View at Scopus
  44. J. Mallolas, D. Podzamczer, A. Milinkovic et al., “Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a lpv/r-containing haart: the atazip study,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 1, pp. 29–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. T. Nguyen, S. A. Eaton, A. M. Bain et al., “Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus,” Pharmacotherapy, vol. 28, no. 3, pp. 323–330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Soriano, P. García-Gasco, E. Vispo et al., “Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 1, pp. 200–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  48. M. Tungsiripat and J. A. Aberg, “Dyslipidemia in HIV patients,” Cleveland Clinic Journal of Medicine, vol. 72, no. 12, pp. 1113–1120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Sekar, S. Spinosa-Guzman, and K. Marien, “Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin,” in Proceedings of the 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, April 2007, abstract no. 54.
  50. C. J. Fichtenbaum and J. G. Gerber, “Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection,” Clinical Pharmacokinetics, vol. 41, no. 14, pp. 1195–1211, 2002. View at Google Scholar · View at Scopus
  51. G. J. Moyle, M. Lloyd, B. Reynolds, C. Baldwin, S. Mandalia, and B. G. Gazzard, “Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy,” AIDS, vol. 15, no. 12, pp. 1503–1508, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. J. G. Gerber, S. L. Rosenkranz, C. J. Fichtenbaum et al., “Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study,” Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 3, pp. 307–312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J. J. Kiser, J. G. Gerber, J. A. Predhomme, P. Wolfe, D. M. Flynn, and D. W. Hoody, “Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 5, pp. 570–578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. van der Lee, R. Sankatsing, E. Schippers et al., “Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients,” Antiviral Therapy, vol. 12, no. 7, pp. 1127–1132, 2007. View at Google Scholar · View at Scopus
  55. F. De Lorenzo, M. Boffito, S. Collot-Teixeira et al., “Prevention of atherosclerosis in patients living with HIV,” Vascular Health and Risk Management, vol. 5, no. 1, pp. 287–300, 2009. View at Google Scholar · View at Scopus
  56. E. Negredo, J. Moltó, J. Puig et al., “Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins,” AIDS, vol. 20, no. 17, pp. 2159–2164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Wohl, P. Hsue, S. Richard, et al., “Ezetimibe’s effects on the LDL cholesterol levels of HIV-infected patients receiving HAART,” in Proceedings of the 14th Conference on Retroviruses and. Opportunistic Infections (CROI '07), Los Angeles, Calif, USA, 2007, abstract no. 39.
  58. M. T. Bennett, K. W. Johns, and G. P. Bondy, “Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV,” Lipids in Health and Disease, vol. 6, Article ID 15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Miller, D. Brown, J. Amin et al., “A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia,” AIDS, vol. 16, no. 16, pp. 2195–2200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. J. A. Aberg, R. A. Zackin, S. W. Brobst et al., “A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group study 5087,” AIDS Research and Human Retroviruses, vol. 21, no. 9, pp. 757–767, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. C. J. Fichtenbaum, T.-M. Yeh, S. R. Evans, et al., “Changes in markers of atherogenic dyslipidemia, inflammation, and platelet activation with treatment with pravastatin, fenofibrate, or the combination: results from ACTG A5087,” in Proceedings of the 15th Conference on Retroviruses and. Opportunistic Infections (CROI '08), Boston, Mass, USA, 2008, abstract no. 932.
  62. M. J. Silverberg, W. Levden, L. Hurley et al., “Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection,” Annals of Internal Medicine, vol. 150, no. 5, pp. 301–313, 2009. View at Google Scholar · View at Scopus
  63. J. G. Gerber, D. W. Kitch, C. J. Fichtenbaum et al., “Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 4, pp. 459–466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. P. De Truchis, M. Kirstetter, A. Perier et al., “Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study,” Journal of Acquired Immune Deficiency Syndromes, vol. 44, no. 3, pp. 278–285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Carosi, E. Quiros-Roldan, C. Torti et al., “First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006),” Infection, vol. 35, no. 3, pp. 134–142, 2007. View at Publisher · View at Google Scholar
  66. G. M. N. Behrens and P. Reiss, “Abacavir and cardiovascular risk,” Current Opinion in Infectious Diseases, vol. 23, no. 1, pp. 9–14, 2010. View at Publisher · View at Google Scholar
  67. J. R. Arribas López, “Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker,” Enfermedades Infecciosas y Microbiología Clínica, vol. 26, supplement 11, pp. 23–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. P. H. Keiser, M. G. Sension, E. DeJesus et al., “Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment,” BMC Infectious Diseases, vol. 5, no. 1, article 2, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Katlama, B. Gazzard, J. Mallolas et al., “Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy,” AIDS, vol. 17, no. 12, pp. 1855–1856, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Lafeuillade, N. Clumeck, J. Mallolas et al., “Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the trizal study,” HIV Clinical Trials, vol. 4, no. 1, pp. 37–43, 2003. View at Publisher · View at Google Scholar
  71. G. Rizzardini and A. Capetti, “Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review,” Medical Science Monitor, vol. 12, no. 12, pp. RA269–RA276, 2006. View at Google Scholar · View at Scopus
  72. E. Martínez, J. A. Arnaiz, D. Podzamczer et al., “Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 349, no. 11, pp. 1036–1046, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Negredo, L. Cruz, R. Paredes et al., “Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression,” Clinical Infectious Diseases, vol. 34, no. 4, pp. 504–510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Ruiz, E. Negredo, P. Domingo et al., “Antiretroviral treatment simplification with nevirapine in protease inhibitor—experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 3, pp. 229–236, 2001. View at Google Scholar
  75. J. M. Petit, M. Duong, D. Masson et al., “Serum adiponectin and metabolic parameters in HIV-I-infected patients after substitution of nevirapine for protease inhibitors,” European Journal of Clinical Investigation, vol. 34, no. 8, pp. 569–575, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. M. I. Gonzalez-Tome, J. T. R. Amador, J. M. Peña, M. L. N. Gomez, P. R. Conejo, and P. M. Fontelos, “Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children,” BMC Infectious Diseases, vol. 8, Article ID 144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Estrada, N. G. P. De Villar, M. T. M. Larrad, A. G. López, C. Fernández, and M. Serrano-Rios, “Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy,” Clinical Infectious Diseases, vol. 35, no. 1, pp. 69–76, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. D. J. Ward and J. M. Curtin, “Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles,” AIDS Patient Care and STDs, vol. 20, no. 8, pp. 542–548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. C. K. Schewe, R. Maserati, G. Wassmer, A. Adam, and L. Weitner, “Improved lipid profiles and maintenance of virologic control in heavily pretreated hiv-infected patients who switched from stavudine to tenofovir treatment,” Clinical Infectious Diseases, vol. 42, no. 1, pp. 145–147, 2006. View at Publisher · View at Google Scholar
  80. J. V. R. Madruga, I. Cassetti, J. M. A. H. Suleiman et al., “The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy,” HIV Clinical Trials, vol. 8, no. 6, pp. 381–390, 2007. View at Publisher · View at Google Scholar
  81. J. Ananworanich, R. Nuesch, H. C. F. Côté et al., “Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine—a staccato trial substudy,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1340–1343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Ribera, J. C. Paradiñeiro, A. Curran et al., “Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study),” HIV Clinical Trials, vol. 9, no. 6, pp. 407–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. U. Möbius, M. Lubach-Ruitman, B. Castro-Frenzel et al., “Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia,” Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 2, pp. 174–180, 2005. View at Google Scholar · View at Scopus
  84. M. Sension, J. L. De Andrade Neto, B. Grinsztejn et al., “Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 2, pp. 153–162, 2009. View at Publisher · View at Google Scholar
  85. A. J. Flammer, N. T. T. Vo, B. Ledergerber et al., “Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial,” Heart, vol. 95, no. 5, pp. 385–390, 2009. View at Publisher · View at Google Scholar
  86. R. L. Murphy, B. Berzins, C. Zala et al., “Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy,” AIDS, vol. 24, no. 6, pp. 885–890, 2010. View at Publisher · View at Google Scholar
  87. M. Colafigli, S. Di Giambenedetto, L. Bracciale, E. Tamburrini, R. Cauda, and A. De Luca, “Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen,” HIV Medicine, vol. 9, no. 3, pp. 172–179, 2008. View at Publisher · View at Google Scholar · View at Scopus